Mirena 52 MG systems
Ended Awarded Last action
- Contract number
- SPE2DR26FQHV1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $2,737
Award facts
- Contract value 100% obligated
- $2,737.40 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325411 Medicinal and Botanical Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,737.40 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Mirena 52 mg contraceptive systems. The contract, issued on January 26, 2026, with an ultimate completion date of February 17, 2026, operates on a firm fixed-price basis with no set-aside designation, allowing the contractor to compete in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to establish multiple regional prime vendor contractors for the Department of Defense's pharmaceutical supply needs.
DMS Pharmaceutical Group has demonstrated substantial federal contracting capability as a critical supplier within the military healthcare pharmaceutical supply chain since its System for Award Management registration in July 2001. As the prime contractor on this delivery order, the company leverages its comprehensive product portfolio spanning branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables to support recurring medical supply requirements across Department of Defense healthcare facilities worldwide. The PPV-G GEN V contract, established in November 2025 with a ceiling value of $499,999,999 and completion date of December 31, 2036, encompasses a 30-month base period with three 30-month option periods, positioning DMS Pharmaceutical Group to fulfill the diverse and specialized pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FQHV1?
SPE2DR26FQHV1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 26, 2026.
How much is contract SPE2DR26FQHV1 worth?
The government has obligated $2,737 on SPE2DR26FQHV1.
Is contract SPE2DR26FQHV1 an order under another contract?
Yes. SPE2DR26FQHV1 is a delivery order under SPE2DR25D9759, an indefinite delivery contract.
Was contract SPE2DR26FQHV1 competed?
The extent of competition for SPE2DR26FQHV1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award